| Literature DB >> 32416370 |
Marcello Naccarato1, Ilario Scali2, Sasha Olivo2, Miloš Ajčević3, Alex Buoite Stella2, Giovanni Furlanis2, Carlo Lugnan2, Paola Caruso2, Alberto Peratoner4, Franco Cominotto4, Paolo Manganotti2.
Abstract
BACKGROUND: The COVID-19 pandemics required several changes in stroke management and it may have influenced some clinical or functional characteristics. We aimed to evaluate the effects of the COVID-19 pandemics on stroke management during the first month of Italy lockdown. In addition, we described the emergency structured pathway adopted by an Italian University Hub Stroke Unit in the cross-border Italy-Slovenia area.Entities:
Keywords: COVID; Coronavirus; Ischemic stroke; Outcome; Stroke unit
Mesh:
Year: 2020 PMID: 32416370 PMCID: PMC7201240 DOI: 10.1016/j.jns.2020.116889
Source DB: PubMed Journal: J Neurol Sci ISSN: 0022-510X Impact factor: 3.181
Fig. 1Epidemic outbreak in FVG region (data from Italian Ministry of Health daily official report, see http://www.salute.gov.it/portale/home.html). During the study period (9th March - 9th April 2020) a progressive increase of confirmed COVID-19 cases in FVG was observed, up to 2′299 total confirmed cases. Over the same period, there was a modest increase of hospitalized patients that reached a plateau in the first days of April. The same applied to the number of ICU patients. During the study period, 16 patients were admitted to the Stroke Unit, 9 of which as ‘stroke code’.
Fig. 2Block diagram of protocol for acute stroke management during the COVID-19 pandemics in our hub university hospital. Following national and institutional regulations, all the patients and healthcare personnel were provided with personal protection equipment (PPE). All patients from the Giuliano-Isontina area with acute onset of neurological symptoms compatible with suspected cerebrovascular disease were transported to the Trieste University Hospital Emergency Department (ED) and the neurologist advice was immediately requested. The pre-hospital healthcare personnel identified possible COVID-19 positive cases if symptoms such as cough, fever, flu-like syndrome or dyspnea were present or reported. If the patient was suspected of being positive to SARS-CoV-2 infection, they were admitted to a specific protected ‘dirty ED area’ (separated from the ‘clean ED area’, for non-suspected COVID-19 patients) where neurological examination and urgent hematological tests were performed. In “code stroke” patients, Multimodal CT (including Non-enhanced CT, CT angiography of the supra-aortic and intracranial arteries, and - in the cases of ischemic strokes - whole brain volume CT Perfusion) was performed as usual. After neuroradiological examination in suspected COVID-19 positive patients, the CT-room and equipment were properly sanitized. Patients with diagnosis of definite or probable acute cerebrovascular disease were hospitalized in Stroke Unit where, similarly to the ED, ‘dirty’ and ‘clean’ areas were arranged.
In both areas, patients were treated with the usual standardized protocols. All patients admitted to ED with stroke symptoms performed nasopharyngeal swab during the assessment process. The median time from swab collection to examination results was 4 h. If COVID-19 diagnosis was confirmed, the patient was transferred to a protected intensive care unit (ICU) or other wards dedicated to COVID-19 for sub-acute care.
Participants' demographics, clinical, neuroimaging data and pre-hospital and intrahospital management characteristics of patients admitted in COVID-19 period versus no-COVID-19 period. Data are presented as medians (IQR) and frequencies.
| Personal characteristics | COVID-19 (2020) | no-COVID-19 (2019) |
|---|---|---|
| (n = 16) | (n = 29) | |
| Age [y] | 77 (67–81) | 78 (70–85) |
| Female:Male | 10:6 | 17:12 |
| Final diagnosis | ||
| Ischemic stroke (%) | 14 (88%) | 23 (79%) |
| Haemorrhagic stroke (%) | 1 (6%) | 2 (7%) |
| TIA (%) | 1 (6%) | 4 (14%) |
| SUSO (%) | ||
| Code stroke (%) | 9 (56%) | 17 (59%) |
| rTPA alone (%) | 4 (25%) | 10 (35%) |
| rTPA + EVT (%) | 2 (13%) | 2 (7%) |
| EVT alone (%) | 0 (0%) | 1 (3%) |
| Timespan in treated patients | ||
| Alert – admission [min] | 128 (56–146) | 91 (46–165) |
| Door to needle [min] | 51 (41–58) | 57 (40–109) |
| Door to groin [min] | 81 (74–87) | 83 (70–99) |
| Neurorad. assessment | ||
| ASPECTS | 10 (8–10) | 10 (9–10) |
| Large vessel occlusion (%) | 4 (25%) | 7 (24%) |
| NIHSS at baseline | 10 (3–18) | 6 (3–11) |
| NIHSS > 10 (%) | ||
| NIHSS at discharge | 5 (1–17) | 1 (0–6) |
| Barthel index at baseline | ||
| Barthel index at discharge | ||
| mRS 0–2 anamnestic (%) | 16 (100%) | 29 (100%) |
| mRS 0–2 at discharge (%) | 4 (25%) | 14 (48%) |
| Intrahospital mortality (%) | 2 (12%) | 3 (10%) |
| Bamford classification (%) | ||
| TACI | 4 (27%) | 5 (19%) |
| PACI | 9 (60%) | 13 (48%) |
| LACI | 0 | 4 (15%) |
| POCI | 2 (13%) | 5 (18%) |
| TOAST (%) | ||
| Atherotrombotic | 1 (6%) | 3 (11%) |
| Small vessel | 0 | 4 (15%) |
| Cardioembolic | 7 (47%) | 9 (33%) |
| Cryptogenic | 7 (47%) | 10 (37%) |
| Other | 0 | 1 (4%) |
| Risk factors (%) | ||
| Hypertension | 15 (94%) | 22 (76%) |
| Diabetes | 6 (37%) | 8 (28%) |
| Dyslipidemia | 10 (62%) | 18 (62%) |
| Atrial Fibrillation | 7 (44%) | 10 (34%) |
| Ischemic cardiomyopathy | 2 (12%) | 6 (21%) |
| Infective complication (%) | 5 (33%) | 3 (10%) |
| Pneumonia | 3 (19%) | 2 (7%) |
| Antibiotic treatment | 5 (31%) | 4 (14%) |
| Lenght of hospitalization (%) | 13 (12–16) | 18 (11–24) |
| Rehab. treatment (%) | 7 (44%) | 15 (52%) |
| Admission – Rehab (day) | 3 (2–5) | 4 (2–4) |
| Number of advice | 1 (1–2) | 3 (2–3) |
| Complete stroke work–up (%) | ||
| Destination at discharge (%) | ||
| Home | 6 (43%) | 12 (46%) |
| Rehabilitation | 2 (15%) | 4 (15%) |
| Neuro spoke | 5 (35%) | 2 (8%) |
| Other | 1 (7%) | 8 (31%)) |
Notes: Participants' reported characteristics. Stroke of Unknown Symptoms Onset (SUSO), thrombolysis (rTPA) and thrombectomy (EVT), modified Rankin Scale (mRS). Results are summarized for patients admitted in our Stroke Unit in COVID-19 period (9 March - 9 April 2020) and in no-COVID-19 period (9 March - 9 April 2019). Bold values for significance value for intergroup comparison. (p < .05).